Economic evaluation of cystic fibrosis screening: A review of the literature

DSpace/Manakin Repository

Search OPUS


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Radhakrishnan, M
dc.contributor.author van Gool, K
dc.contributor.author Hall, J
dc.contributor.author Delatycki, M
dc.contributor.author Massie, J
dc.date.accessioned 2010-05-28T09:51:12Z
dc.date.issued 2008-02
dc.identifier.citation Health Policy, 2008, 85 (2), pp. 133 - 147
dc.identifier.issn 0168-8510
dc.identifier.other C1 en_US
dc.identifier.uri http://hdl.handle.net/10453/9685
dc.description.abstract Objectives: To critically examine the economic evidence regarding cystic fibrosis (CF) carrier screening and to understand issues relating to the transferability of international findings to any national context for policy decisions. Methods: A systematic literature search identified 14 studies (out of 29 economic studies on CF) focusing on preconception or prenatal screening between 1990 and 2006. These studies were then assessed against international benchmarks on conducting and reporting of economic evaluations, costing methodology used and focusing on the transferability of the evidence to national contexts. Results: The primary outcome measures varied considerably between studies and there was considerable ambiguity and variation on how costs were estimated. The Incremental Cost Effectiveness Ratio (ICER) and net savings, for preconception and prenatal screening were inconsistent and varied significantly, even after adjusting for timing and exchange rates. Differences in screening participation rates, reproductive choices, test sensitivity, cost of test and lifetime cost of care make up a large part of the ICER variations. Conclusion: The heterogeneity in study design, model inputs and reporting of economic evaluations of CF carrier screening makes comparability and transferability across countries and even within countries difficult. This reinforces the need to assess any technology within the relevant context, and to not simply generalize from reported studies. In turn, this adds to the complex task of making efficient resource allocation decisions in the area of CF carrier screening. Our evaluation adds weight to the calls for revisiting the way economic studies are conducted and reported. © 2007 Elsevier Ireland Ltd. All rights reserved.
dc.language eng
dc.relation.isbasedon 10.1016/j.healthpol.2007.07.007
dc.title Economic evaluation of cystic fibrosis screening: A review of the literature
dc.type Journal Article
dc.parent Health Policy
dc.journal.volume 2
dc.journal.volume 85
dc.journal.number 2 en_US
dc.publocation Amsterdam, The Netherlands en_US
dc.identifier.startpage 133 en_US
dc.identifier.endpage 147 en_US
dc.cauo.name BUS.Centre for Health Economics Research and Evaluation en_US
dc.conference Verified OK en_US
dc.for 1605 Policy and Administration
dc.for 1117 Public Health and Health Services
dc.personcode 106498
dc.personcode 020116
dc.personcode 104035
dc.percentage 50 en_US
dc.classification.name Public Health and Health Services en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US
dc.date.activity en_US
dc.location.activity en_US
dc.description.keywords Costing
dc.description.keywords Cystic fibrosis
dc.description.keywords Economic evaluation
dc.description.keywords Screening
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Faculty of Business
pubs.organisational-group /University of Technology Sydney/Faculty of Design, Architecture and Building
pubs.organisational-group /University of Technology Sydney/Strength - Health Economics and Research Evaluation
utslib.copyright.status Closed Access
utslib.copyright.date 2015-04-15 12:17:09.805752+10
pubs.consider-herdc true
utslib.collection.history Closed (ID: 3)
utslib.collection.history Uncategorised (ID: 363)


Files in this item

This item appears in the following Collection(s)

Show simple item record